More lithium gloom ahead: GS and mates
Goldman Sachs isn’t saying ‘told you so’ as lithium prices plummet, hurting many ASX stocks. Instead it’s doubled down – and it has some backup.
Goldman Sachs isn’t saying ‘told you so’ as lithium prices plummet, hurting many ASX stocks. Instead it’s doubled down – and it has some backup.
It’s all coming up roses for Reward Minerals, with set to acquire a $400 million potash project … for $20 million. Get your resources news here.
Neuren Pharma continues to tackle neuro-developmental disorders in children, heading into a Phase 2 trial for its Pitt Hopkins syndrome treatment.
Bitget, one of the world’s leading crypto exchanges, identifies what’s made 2023 a much better year for the market, and trend shifts that could send it all to the moon in 2024.
The brokers at Taylor Collison have given Academies Australasia a big tick, saying the education stock is well placed to welcome back international students.
Retail interest in physical gold has soared in 2023 amid bank failures, inflation, recession and war. But there are pitfalls and alternatives to consider.
Many experts expect a decades-long copper bull market – but two noted contrarian investors warn that new tech could crush prices … again.
It has historically been easy to take a tumble when chasing rare earths elements. And Arafura plans to learn the lessons of the past as it saddles up in the NT.
Hartshead Resources has further de-risked Phase 1 development plans for its UK Southern Gas Basin assets after negotiating an option with its farm-in partner, RockRose Energy.
ASX medical stock Compumedics pumped by 75 per cent after the FDA cleared its sleep device, Somfit, to be marketed in the lucrative US market.
After ailing for most of the year, the ASX Healthcare Index lifted by 10 per cent in November. It’s a sign of things to come, says Janus Henderson.
Momentum’s not always easy to achieve, but once it’s in place, things tend to roll on. These stocks are moving in the right direction.
The hunt for uranium is starting to pick up, as ASX stocks get drills spinning on a wide variety of prospects here and overseas. Here’s what we expect this month.
We may be stressed, but we still have an appetite for fast food, it seems. That is, right up until a chain gets hungry and super-sizes prices, says Tim Boreham.
You’d think that every business bigwig would have a succession plan for when they head to the big board room in the sky. You’d be wrong, says The Secret Broker.
Dalaroo Metals has been rewarded for being in the right place at the right time, with a deal delivering $500,000 in cash and the same in Delta Lithium shares.
S2 Resources, against the odds, secured arguably Australia’s most exciting gold prospect. Now, as drilling starts, the sector is holding its breath.
The tech sector is charging towards year’s end with momentum, after continuing to outperform the ASX 200 in November. There were some big winners.
Australia’s annual climate change statement – and recent news for several stocks – have shown that attention to green initiatives can pay dividends.
Cooper Metals went on the gallop again after a high-grade copper discovery at its Brumby Ridge prospect was confirmed. Get your resources wrap here.
Lithium companies have been finding life a little more difficult lately, but that isn’t stopping these stocks from releasing of shares. Here’s your escrow wrap.
Pilbara Minerals is now the ASX’s most shorted stock. But it’s not alone, with several other lithium miners targeted as ‘white gold’ loses its lustre.
Imugene’s share price pumped after anti-cancer virus VAXINIA was granted FDA Fast Track designation. Here are this month’s biotech winners.
LTR Pharma is set to join the ASX armed with a world-first nasal spray to bring relief to erectile dysfunction sufferers and spontaneity to the bedroom.
Dual-listed Euro Manganese suddenly looks in far better shape, after an injection of $US100 million in funding. Get the latest resources news here.
Clinuvel Pharmaceuticals and ANZ have been under brokers’ microscopes. One has been given a series of ticks, the other … not so much.
These two stocks may deal with cannabis but are determined to be much more than ‘pot peddlers’, as they rely on innovation and medical rigour to forge new paths.
Copper’s performance has been a underwhelming of late. But these nine undervalued ASX stocks are preparing for a seemingly inevitable recovery.
Strange day for ASX resources stocks, with plenty of gains, including MinRex’s early 50 per cent jump, on not much new information.
Good news and bad news for health stocks. Singular Health pumped after securing funds, while a possible tax debt hit Pacific Smiles Group.
Renowned global mining and trading house Glencore has thrown its weight behind Galan Lithium’s Hombre Muerto West project, with an offtake and funding deal.
Impact boss Dr Mike Jones is great at mining and rocks. But when it comes to ESG, he’s happy for a little help. Enter, Socialsuite.
The Secret Broker was trying to discover Man of Steel Sanjeev Gupta’s net worth. Easy enough you’d think but not so. Even AI was no help.
Investors looking for takeover action in 2024 should note a growing hunger in the small-cap financial advisory sector, says Tim Boreham.
Lithium project developers often suffer capex blowouts but not Vulcan, which now expects lower start-up costs at its Zero Carbon Lithium project, with the same production capacity.
Antilles Gold has intersected high grade copper – including a top hit of 11m grading 4.7 per cent copper – at the El Pilar copper-gold porphyry deposit in central Cuba.
Oil prices have slid a little over recent weeks, which is good news for Aussie consumers. And so is the rise of renewable energy in the eastern states.
Getting a mining project off the ground these days can be a tough test. Resources investment house Argonaut reckons these 11 are most likely to pass.
Panoramic Resources has commissioned a strategic review that could result in a complete or partial sale of its flagship Savannah nickel mine in WA.
Two lithium stocks are riding an exhilarating wave on Thursday, with one up more than 50 per cent, and the other jumping 44 per cent.
With rare earths elements prices switching up a gear, these ASX companies are tackling the sometimes difficult and expensive quest to mine them.
Uvre has staked the South Pass hard rock lithium project in Wyoming at a time when the US government is actively funding domestic sources of strategic minerals.
The Andover project looks an absolute giant after another flurry of assay results confirmed Target Area 3 as one of Azure Minerals’ ‘highest ranked lithium target’”.
CSIRO-led modelling has revealed major extensions to rare earths basins within OD6 Metals’ intriguing Splinter Rock project near Esperance, WA.
Argenica Therapeutics has achieved a key milestone, with the US FDA granting orphan drug designation for ARG-007 for the treatment of hypoxic ischaemic encephalopathy.
Bond yields are showing signs of fatigue, says senior analyst Kyle Rodda. And he has nominated three ASX stocks with a history of shining in this scenario.
Good neighbours never go astray, and Errawarra Resources has some corkers close to its Andover West project. So it’s no surprise ERW has been surging.
Impatient investors drove down cardiac disease specialist EBR Systems’ price by double digits on Wednesday, after a delay in key FDA approvals was announced.
Melodiol Global Health is delivering on its strategy to bring core operating subsidiaries to profitability, with Health House International generating $1 million in October.
A new high-growth fund has just made it much easier for Australians to get a foothold in the lucrative US residential property market.
Original URL: https://www.heraldsun.com.au/business/stockhead/page/49